Apollomics Inc. Reports Phase 3 Trial Results for Uproleselan
Ticker: APLMW · Form: 6-K · Filed: Dec 20, 2024 · CIK: 1944885
| Field | Detail |
|---|---|
| Company | Apollomics Inc. (APLMW) |
| Form Type | 6-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-results, biotech, regulatory-filing
TL;DR
APLM released Phase 3 China trial results for uproleselan on Dec 20, 2024.
AI Summary
On December 20, 2024, Apollomics Inc. announced the results of its Phase 3 bridging trial for uproleselan in China. The company issued a press release detailing these findings, which is being furnished to the SEC as Exhibit 99.1.
Why It Matters
The results of this Phase 3 bridging trial are crucial for Apollomics' potential regulatory submissions and commercialization efforts for uproleselan in China.
Risk Assessment
Risk Level: medium — The filing reports trial results, which can significantly impact a biotech company's stock price and future prospects.
Key Players & Entities
- Apollomics Inc. (company) — Registrant
- uproleselan (drug) — Drug in Phase 3 trial
- December 20, 2024 (date) — Date of press release and filing
FAQ
What specific results were announced for the Phase 3 bridging trial of uproleselan in China?
The filing states that Apollomics Inc. announced results for its Phase 3 bridging trial of uproleselan in China on December 20, 2024, but the specific results are detailed in the press release furnished as Exhibit 99.1, which is not fully provided in this excerpt.
What is the significance of a 'bridging trial' in this context?
A bridging trial is typically conducted to provide data that can support the use of a drug approved in one region (e.g., the US) in another region (e.g., China), often by demonstrating similar efficacy and safety in a local population.
What is uproleselan?
Uproleselan is the drug that Apollomics Inc. is testing in its Phase 3 bridging trial in China, as indicated by the filing.
Where is Apollomics Inc. headquartered?
Apollomics Inc.'s principal executive office is located at 989 E. Hillsdale Blvd., Suite 220, Foster City, California 94404.
What is the purpose of filing a Form 6-K?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information to the SEC that the company has made or is required to make public in its home country.
Filing Stats: 354 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-12-20 08:31:25
Filing Documents
- d853425d6k.htm (6-K) — 11KB
- d853425dex991.htm (EX-99.1) — 10KB
- g853425g1220055153810.jpg (GRAPHIC) — 3KB
- 0001193125-24-282519.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Apollomics Inc. Date: December 20, 2024 By: /s/ Guo-Liang Yu Guo-Liang Yu, Ph.D. Chief Executive Officer 3